- Risk that product candidates are not developed to market maturity or are developed only with delay; Unforeseeable complications or side effects may occur in clinical trials; Lack of or reduced sales or a delay in market approval for new product candidates; Price negotiations with health insurers; Growing competition; Changes in healthcare legislation; Currency risk; Insufficient capacity to produce necessary quantities; Increased complexity of communications; Litigation from commercial partnerships; Insufficient protection of existing knowledge or patents; COVID-19 impact on clinical trials and patient recruitment; Supplier, licensor, and CRO availability and performance due to COVID-19.
BioNTech SE
Greenhouse gas emissions & sustainability report data
In its 2020 reporting, BioNTech SE disclosed greenhouse gas emissions of 6.2K t CO2e. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
6.2K t CO2e
2020
✅ Reported Environmental Achievements
- Reduced emission intensity (Scope 1 & 2 emissions from electricity and heat generation divided by FTEs) from 2.56 t CO2e/FTE in 2019 to 2.35 t CO2e/FTE in 2020; Reduced emission intensity 2 (Scope 1 & 2 emissions from electricity, heat generation plus Scope 3 emissions from upstream process chain divided by FTEs) from 4.43 t CO2e/FTE in 2019 to 3.18 t CO2e/FTE in 2020.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Further reduce employee turnover rate and become employer of choice
📅 Medium-term
- Climate neutral by 2030
🌱 ESG Focus Areas
Climate ProtectionAttractive EmployerInnovationCompliance